Details for Patent: 7,579,473

Which drugs does patent 7,579,473 protect, and when does it expire?

Patent 7,579,473 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has seventy-four patent family members in seventeen countries.

Summary for Patent: 7,579,473

Title:	c-Met modulators and methods of use
Abstract:	The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s):	Lynne Canne Bannen, Diva Sze-Ming Chan, Timothy Patrick Forsyth, Richard George Khoury, James William Leahy, Morrisson B. Mac, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Yong Wang, Wie Xu
Assignee:	Exelixis Inc
Application Number:	US12/393,806
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,579,473
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 7,579,473

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No			Y	Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes			Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No			Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No			Y	Y

International Family Members for US Patent 7,579,473

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2213661		C300678	Netherlands
European Patent Office	2213661		CA 2014 00039	Denmark
European Patent Office	2213661		PA2014033	Lithuania
European Patent Office	2213661		C20140029 00117	Estonia